• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
    • Cardiovascular
    • Orthopedics
  • Wall Street Beat
    • Funding Roundup
    • Mergers & Acquisitions
  • Podcasts & Webinars
    • Podcasts
    • Webinars
  • Resources
    • About MassDevice
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech 100 Index
    • Videos
    • Whitepapers
  • DeviceTalks Tuesdays
  • Coronavirus: Live updates

Cytori Therapeutics

Cytori Therapeutics posts mixed Q2

August 11, 2017 By Sarah Faulkner

Shares in Cytori Therapeutics (NSDQ:CYTX) fell today after the biotech missed sales expectations on Wall Street with its second quarter results, but topped EPS estimates. The San Diego, Calif.-based company posted a net loss of -$6 million on sales of $1.5 million for the 3 months ended June 30, for bottom-line growth of 6% on sales loss […]

Filed Under: Drug-Device Combinations, MassDevice Earnings Roundup, Regenerative Medicine, Wall Street Beat Tagged With: Cytori Therapeutics

Cytori launches next-gen Celution cell therapy tech

June 1, 2017 By Sarah Faulkner

Cytori Therapeutics (NSDQ:CYTX) said today that the next-gen version of its Celution cell therapy device is available for pre-order and that the 1st shipments will start in the 3rd quarter of 2017. The San Diego-based company’s Celution system automates the extraction and concentration of autologous, clinical-grade adipose-derived regenerative cells. The next-gen Celution tech includes new […]

Filed Under: Drug-Device Combinations, Regenerative Medicine, Wall Street Beat, Wound Care Tagged With: Cytori Therapeutics

Cytori prices $9.5m public offering

April 11, 2017 By Sarah Faulkner

Cytori Therapeutics (NSDQ:CYTX) said today that it priced an underwritten public offering of 8.6 million shares of common stock at $1.10 apiece. The company plans to bring in $9.5 million. Cytori granted a 45-day underwriter’s option to purchase up to 15% of additional shares of common stock. The offering is expected to close on April […]

Filed Under: Funding Roundup, Regenerative Medicine, Wall Street Beat Tagged With: Cytori Therapeutics

Cytori wins FDA nod for cell therapy pilot trial

April 10, 2017 By Sarah Faulkner

Cytori Therapeutics (NSDQ:CYTX) said today that the FDA approved an Investigational Device Exemption for a pilot trial of the company’s cell therapy in patients with thermal burn injury. The Relief trial is a part of Cytori’s ongoing R&D efforts under its contract with the U.S. Dept. of Health & Human Services’ Biomedical Advanced Research and […]

Filed Under: Clinical Trials, Food & Drug Administration (FDA), Regenerative Medicine, Regulatory/Compliance, Wall Street Beat Tagged With: Cytori Therapeutics

Cytori launches nanoparticle program after acquiring Azaya Therapeutics

February 16, 2017 By Sarah Faulkner

Cytori Therapeutics (NSDQ:CYTX) said yesterday that it completed its acquisition of San Antonio-based Azaya Therapeutics and its nanoparticle cancer drugs. In late January, San Diego-based Cytori said it planned to buy Azaya in a stock deal, offering Azaya shareholders $2 million in CTYX stock. Cytori also said that it paid $2 million upfront for costs associated […]

Filed Under: Drug-Device Combinations, Mergers & Acquisitions, Pharmaceutical, Wall Street Beat Tagged With: Azaya Therapeutics, Cytori Therapeutics

Cytori buys Azaya’s nanoparticle tech in stock deal

January 20, 2017 By Sarah Faulkner

Cytori Therapeutics (NSDQ:CYTX) said this week that it bought San Antonio-based Azaya Therapeutics and its nanoparticle cancer drugs in a stock deal. Azaya shareholders will receive $2 million in CTYX stock. San Diego-based Cytori will also pay $2 million upfront for costs associated with Azaya’s new manufacturing facility in San Antonio. Cytori will acquire a […]

Filed Under: Drug-Device Combinations, Mergers & Acquisitions, Oncology, Pharmaceutical, Wall Street Beat Tagged With: Azaya Therapeutics, Cytori Therapeutics

Cytori touts regenerative cell therapy data

October 24, 2016 By Sarah Faulkner

Cytori Therapeutics (NSDQ:CYTX) touted the publication of preclinical safety and efficacy data for its cell therapy treatment for combined radiation and thermal injury. The San Diego-based company said the current healthcare system is ill-prepared to care for large numbers of patients that require simultaneous treatment and that patients with severe burns commonly suffer with prolonged […]

Filed Under: Regenerative Medicine, Research & Development Tagged With: Cytori Therapeutics

Cytori Therapeutics closes $17m funding round

June 16, 2016 By Fink Densford

Cytori Therapeutics (NASDAQ:CYTX) said today it closed a $17.1 million rights offering round, floating 6.7 million units at $2.55 each. Through the rights offering, each of the 6.7 million units consisted of an equal amount of shares of common stock and 3.4 million warrants exercisable for 1 share of common stock at $3.06 per share, the company […]

Filed Under: Business/Financial News Tagged With: Cytori Therapeutics

Philips Healthcare’s India chief takes over new emerging markets biz | Personnel Moves

September 9, 2015 By Fink Densford

Royal Philips (NYSE:PHG) has promoted its India managing director and CEO Krishna Kumar to a position managing its emerging healthcare business division, according to The Times of India. Kumar is slated to continue as managing director of Philips India division until December, at which point he will lead the development of consumer and profesisonal healthcare […]

Filed Under: Business/Financial News Tagged With: becton dickinson, Boston Scientific, CryoLife, Cytori Therapeutics, Daxor Corp., Electromed, Globus Medical, Haemonetics, lombardmedical, Personnel Moves, Philips, TransEnterix

FDA OKs Phase II trial for Kerastem’s alopecia treatment

July 28, 2015 By Fink Densford

Kerastem Technologies said today it won Investigative Device Exemption approval from the FDA to conduct a clinical trial of its Celution technology used to treat female and early male androgenic alopecia. The 70-patient phase II Style trial will follow-up on initial clinical work in Europe and Japan that the company used for IDE submission, the company […]

Filed Under: Clinical Trials, Cosmetic/Aesthetic, Regulatory/Compliance Tagged With: Cytori Therapeutics, Kerastem Technologies

HeartWare lands FDA OK for extended trial ahead of PMA review | Regulatory Roundup

March 19, 2012 By MassDevice staff Leave a Comment

MassDevice.com Regulatory Roundup

 HeartWare lands approval for a 4th round of pivotal trials for its HVAD ventricular assist device

Filed Under: Food & Drug Administration (FDA), News Well, Pre-Market Approval (PMA) Tagged With: Biovo Technologies, Boston Scientific, Cambridge Heart Inc., Cardiac Rhythm Management, Clinical Trials, Cytori Therapeutics, HeartWare International Inc., Regulatory Roundup, Sunshine Heart Inc., SurgiTools, Ulthera Inc.

  • Go to page 1
  • Go to page 2
  • Go to Next Page »

Primary Sidebar

DeviceTalks Weekly

May 20, 2022
DeviceTalks Boston Post-Game – Editors’ Top Moments, Insulet’s Eric Benjamin on future of Omnipod 5
See More >

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Medtech news in a minute?
We Deliver!

MassDevice Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World

Device Talks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our Device Talks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us
Add us on Facebook Follow us on Twitter Connect with us on LinkedIn Follow us on YouTube

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS